TAR RNA binding protein (TRBP) belongs to an RNA binding protein family that includes the double‐stranded RNA‐activated protein kinase (PKR), Drosophila Staufen and Xenopus xlrbpa . One member of this family, PKR, is a serine/threonine kinase which has anti‐viral and anti‐proliferative effects. In this study we show that TRBP is a cellular down‐regulator of PKR function. Assaying expression from an infectious HIV‐1 molecular clone, we found that PKR inhibited viral protein synthesis and that over‐expression of TRBP effectively countered this inhibition. In intracellular and in cell‐free assays we show that TRBP directly inhibits PKR autophosphorylation through an RNA binding‐independent pathway. Biologically, TRBP serves a growth‐promoting role; cells that over‐express TRBP exhibit transformed phenotypes. Our results demonstrate the oncogenic potential of TRBP and are consistent with the notion that intracellular PKR function contributes physiologically towards regulating cellular proliferation.
MicroRNAs (miRNAs) play diverse roles in regulating cellular and developmental functions. We have profiled the miRNA expression in peripheral blood mononuclear cells from 36 HIV-1 seropositive individuals and 12 normal controls. The HIV-1-positive individuals were categorized operationally into four classes based on their CD4+ T-cell counts and their viral loads. We report that specific miRNA signatures can be observed for each of the four classes.
1 September 2000 in The Journal of Infectious Diseases
Background: Identification of risk factors of severe coronavirus disease 2019 (COVID‐19) is critical for improving therapies and understanding severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pathogenesis. We analyzed 184 patients hospitalized for COVID‐19 in Livingston, New Jersey for clinical characteristics associated with severe disease. The majority of patients with COVID‐19 had diabetes mellitus (DM) (62.0%), Pre‐DM (23.9%) with elevated fasting blood glucose (FBG), or a body mass index >30 with normal hemoglobin A1c (HbA1C) (4.3%). SARS‐CoV‐2 infection was associated with new and persistent hyperglycemia in 29 patients, including several with normal HbA1C levels. Forty‐four patients required intubation, which occurred significantly more often in patients with DM as compared with non‐diabetics. Severe COVID‐19 occurs in the presence of impaired glucose metabolism in patients, including those with DM, preDM, and obesity. COVID‐19 is associated with elevated FBG and several patients presented with new onset DM or in DKA. The association of dysregulated glucose metabolism and severe COVID‐19 suggests that SARS‐CoV‐2 pathogenesis involves a novel interplay with glucose metabolism. Exploration of pathways by which SARS‐CoV‐2 interacts glucose metabolism is critical for understanding disease pathogenesis and developing therapies.
Accumulating data suggest that the state of the vaginal epithelium affects a woman's risk of HIV vaginal transmission and several human and non-human primate studies have shown that the rate of HIV or SIV vaginal transmission is decreased when estrogen is dominant. Systemic estrogen can protect against SIV vaginal transmission. To determine the safety and efficacy of topical estrogen in preventing SIV vaginal transmission. The non-human primate model of HIV vaginal transmission was used to assess vaginal estriol cream in ovariectomized macaques. Twelve macaques were treated intravaginally with estriol and eight with placebo cream twice a week. The vaginal and systemic effects of estriol were determined by colposcopy and serum luteinizing hormone, levels of which would decline in the presence of systemic estrogen. After 5 weeks of therapy, the animals were challenged vaginally with pathogenic SIVmac251. Vaginal estriol resulted in minimal serum estriol levels and had no effect on serum luteinizing hormone levels. Vaginal epithelia cornified and thickened significantly in response to estriol therapy. One of the estriol-treated animals became infected after this single challenge, while six of the control animals became infected (P = 0.0044). These data demonstrate that topical vaginal estriol can strongly protect against SIV vaginal transmission, while having no detectable systemic effect. These results support the study of topical vaginal estriol in preventing HIV vaginal transmission in at-risk women.
1 June 2001 in Infectious Disease Clinics of North America